Based on the Anebulo Pharmaceuticals Inc stock forecast from 1 analysts, the average analyst target price for Anebulo Pharmaceuticals Inc is USD 8.00 over the next 12 months. Anebulo Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Anebulo Pharmaceuticals Inc is Bearish, which is based on 1 positive signals and 7 negative signals. At the last closing, Anebulo Pharmaceuticals Inc’s stock price was USD 1.08. Anebulo Pharmaceuticals Inc’s stock price has changed by +6.93% over the past week, -31.65% over the past month and -61.29% over the last year.
No recent analyst target price found for Anebulo Pharmaceuticals Inc
No recent average analyst rating found for Anebulo Pharmaceuticals Inc
Company Overview Anebulo Pharmaceuticals Inc
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas. Read Less
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, ...Read More
Frequently Asked Questions About Anebulo Pharmaceuticals Inc (ANEB) Stock
Based on ratings from 1 analysts Anebulo Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on ANEB's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for ANEB is USD 8.00 over the next 12 months. The maximum analyst target price is USD 8 while the minimum anlayst target price is USD 8.
Unfortunately we do not have enough data on ANEB's stock to indicate if its overvalued.
The last closing price of ANEB's stock was USD 1.08.
The most recent market capitalization for ANEB is USD 0.04B.
Based on targets from 1 analysts, the average taret price for ANEB is projected at USD 8.00 over the next 12 months.
This means that ANEB's stock price may go up by +640.74% over the next 12 months.
We can't find any ETFs which contains Anebulo Pharmaceuticals Inc's stock.
As per our most recent records Anebulo Pharmaceuticals Inc has 2 Employees.
Anebulo Pharmaceuticals Inc's registered address is 1017 Ranch Road 620 South, Lakeway, TX, United States, 78734.
You can get more information about it from Anebulo Pharmaceuticals Inc's website at https://www.anebulo.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Anebulo Pharmaceuticals Inc (ANEB) Stock
Based on ratings from 1 analysts Anebulo Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on ANEB's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for ANEB is USD 8.00 over the next 12 months. The maximum analyst target price is USD 8 while the minimum anlayst target price is USD 8.
Unfortunately we do not have enough data on ANEB's stock to indicate if its overvalued.
The last closing price of ANEB's stock was USD 1.08.
The most recent market capitalization for ANEB is USD 0.04B.
Based on targets from 1 analysts, the average taret price for ANEB is projected at USD 8.00 over the next 12 months.
This means that ANEB's stock price may go up by +640.74% over the next 12 months.
We can't find any ETFs which contains Anebulo Pharmaceuticals Inc's stock.
As per our most recent records Anebulo Pharmaceuticals Inc has 2 Employees.
Anebulo Pharmaceuticals Inc's registered address is 1017 Ranch Road 620 South, Lakeway, TX, United States, 78734.
You can get more information about it from Anebulo Pharmaceuticals Inc's website at https://www.anebulo.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ANEB !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
